Corcept Therapeutics (CORT) is back in focus after presenting new CATALYST and MOMENTUM trial data at the American Diabetes Association meetings, highlighting how Korlym might affect difficult-to-control diabetes and resistant hypertension.

Corcept’s recent news has added to an already strong run, with a 30 day share price return of 48.22% and a 90 day share price return of 129.67%. The 5 year total shareholder return of 253.35% points to momentum that has built over a longer period.

If Korlym’s new data has you rethinking where medical breakthroughs could come from next, it may be worth scanning for other healthcare related AI opportunities through the 39 healthcare AI stocks

With Corcept’s share price already up sharply and the stock trading at only a small implied discount to the US$88 analyst target and a modest intrinsic discount of about 7%, the key question is clear: is there still an opportunity here, or has the market already priced in future growth?

Most Popular Narrative: 11.9% Undervalued

With Corcept’s fair value in the narrative set at $88 against a last close of $77.49, the story centers on how future growth might bridge that gap.

The publication of the CATALYST study and the resulting increased awareness and screening for hypercortisolism among physicians are expanding the potential addressable patient pool, which is expected to drive significant acceleration in revenue growth over the next several years.

Anticipated regulatory approvals for relacorilant in both hypercortisolism (end of this year) and platinum-resistant ovarian cancer (next year), supported by clinically differentiated safety and efficacy data, create major new revenue and margin expansion opportunities as the company moves past single-product dependence.

Want to see what sits behind that fair value gap? The narrative leans on a steep multi year revenue ramp, sharply higher margins, and a reset earnings base that transforms today’s profit profile.

At the core of this narrative is a fair value of $88 per share, built using a 7.11% discount rate and anchored in analyst expectations for both revenue and earnings over several years. Corcept currently reports revenue of $769.1m and net income of $46.7m, which implies a relatively low net margin today compared with what the narrative assumes for the future.

Those assumptions include faster top line expansion, a much higher profit margin, and a future P/E multiple that is lower than the current industry figure. Together, they form the bridge between current financials and the $88 fair value that sits modestly above the $88 analyst consensus target and slightly above the $83.61 SWS DCF estimate referenced elsewhere.

Result: Fair Value of $88 (UNDERVALUED)

However, the narrative can unwind quickly if Korlym faces faster than expected generic pressure, or if relacorilant or Lifyorli encounter regulatory or uptake setbacks.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of optimism and caution feels familiar, use it as a prompt to move quickly and test the story against the facts for yourself by weighing the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Corcept has sharpened your focus, do not stop here. Broader context across sectors can help you spot patterns and opportunities you might otherwise miss.

• Target steadier growth potential by checking companies with lower risk profiles through the 63 resilient stocks with low risk scores
• Hunt for strong businesses priced below their assessed worth using the 46 high quality undervalued stocks
• Spot lesser known opportunities with solid fundamentals before others catch on by scanning the screener containing 21 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.